EPISODE · Jun 24, 2026 · 5 MIN
EHA2026 | What are the updated 4-year results from the phase III DREAMM-7 trial in RRMM?
from Multiple Myeloma Hub
During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Multiple Myeloma Hub spoke with Vania Tietsche de Moraes Hungria, Clínica São Germano, São Paolo, BR. We asked, What are the updated 4-year results from the phase III DREAMM-7 trial in RRMM? This educational resource is independently supported by GSK. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence. Hosted on Acast. See acast.com/privacy for more information.
What this episode covers
During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Multiple Myeloma Hub spoke with Vania Tietsche de Moraes Hungria, Clínica São Germano, São Paolo, BR. We asked, What are the updated 4-year results from the phase III DREAMM-7 trial in RRMM? This educational resource is independently supported by GSK. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence. Hosted on Acast. See acast.com/privacy for more information.
NOW PLAYING
EHA2026 | What are the updated 4-year results from the phase III DREAMM-7 trial in RRMM?
No transcript for this episode yet
Similar Episodes
Apr 6, 2026 ·25m
Mar 30, 2026 ·27m